Skip to Main Content

Beyondspring’s stock price tripled in August after the New York drug maker said its experimental treatment helped patients with advanced lung cancer live longer. But detailed results presented Monday revealed issues with the conduct and analysis of the clinical trial — leaving the company’s claim of a survival benefit open for debate.

Physicians and investors will argue over the merits of Beyondspring’s drug, called plinabulin, but ultimately, the Food and Drug Administration will decide if it should be approved to treat patients with lung cancer. The company has said it intends to file early next year based on the results from its clinical trial.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment